| Name | Title | Contact Details |
|---|
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
ilumed is a company that helps providers, payers, and other healthcare organizations transition to value-based care models, which focus on quality of health outcomes rather than quantity of services.
Erchonia Medical is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Mckinney, TX. To find more information about Erchonia Medical, please visit www.erchonia.com
Rochester Medical Corporation is a Stewartville, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.